Therapeutic Response

EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Erlotinib in combination with Ramucirumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Cyramza (ramucirumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.